Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Jaguar Health Inc (JAGX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Jaguar Health's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.1979 +0.0179    +9.94%
09:40:24 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 11,312,598
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 0.1887 - 0.2036
Jaguar Health 0.1979 +0.0179 +9.94%

Jaguar Health Inc Company Profile

 
Get an in-depth profile of Jaguar Health Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

49

Equity Type

ORD

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company’s products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Contact Information

Address 200 Pine Street Suite 400
San Francisco, 94104
United States
Phone 415 371 8300
Fax -

Top Executives

Name Age Since Title
Lisa A. Conte 62 2013 Founder, CEO, President & Director
John J. Micek 67 2016 Independent Director
Jonathan B. Siegel 48 2018 Independent Director
James J. Bochnowski 77 2014 Independent Chairman
Sandra M. Swain - 2023 Member of Scientific Advisory Board
Anula K. Jayasuriya 65 2022 Independent Director
Pravin R. Chaturvedi 60 2017 Chief Scientific Officer & Chair of Scientific Advisory Board
Stacey Tinianov - 2023 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

JAGX Comments

Write your thoughts about Jaguar Health Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Muhammad Khawaja
Muhammad Khawaja Apr 26, 2024 3:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Before it fall i suggest to Buy mithra pharmaceuticals @0.22€ and ALIMG ( dmsim ) @0.02 € to get huge profit
Piewhi Van Hirtum
Piewhi Van Hirtum Apr 19, 2024 7:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The share will be listed at 1 dollar again, possibly a reverse stock will take place to achieve this
Muhammad Khawaja
Muhammad Khawaja Apr 17, 2024 6:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buy mithra pharmaceuticals @0.23 € and ALIMG (dmsim) 0.02 € for more gains
Piewhi Van Hirtum
Piewhi Van Hirtum Apr 17, 2024 6:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why is this relevant?
Muhammad Khawaja
Muhammad Khawaja Apr 17, 2024 6:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
It will go sharply up just buy it and you will get huge profit soon
Karel Mannaert
Karel Mannaert Mar 04, 2024 7:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
whats happening ???
Kevin Le
Kevin Le Feb 17, 2024 3:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what is going on 😔
Karel Mannaert
Karel Mannaert Oct 13, 2023 4:37AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
why up last days ?
Vlas Dacian
Vlas Dacian Feb 17, 2023 5:19PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Short more … going bellow 1$ again
Constantino Garcia
Constantino Garcia Sep 27, 2022 5:05PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Pronto eso dice el analista
Marlon Barchi
Marlon Barchi Sep 05, 2022 2:30PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
subirá el precio de la acción...?
sarac mehmet
sarac mehmet Mar 16, 2022 7:04AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
jagx 77.055.000.LOT Market Cap 42Milyon$ Closed 0,55$ 15/03/22 Next Earnings May 20,2022
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email